Came across this article discussing recent advancements in circulating tumor DNA (ctDNA) technology for detecting minimal residual disease (MRD) post-surgery/treatment. Seems like sensitivity is improving, potentially offering a better way to stratify risk and guide adjuvant therapy decisions. Thought folks here, especially those using or considering Signatera/other assays, might find it interesting. Article

  • Chris DavisEnglish
    2·
    8 months ago

    Thanks for sharing, William! I use Signatera and find the tech fascinating, albeit anxiety-inducing. Improved sensitivity is great news, but also potentially means picking up clinically insignificant blips? Always a double-edged sword. Did the article mention specificity improvements too?

    • williammillerOPEnglish
      1·
      8 months ago

      Good point, Christopher. The article touched on specificity challenges but highlighted ongoing efforts to improve algorithms to differentiate between true MRD and other biological noise (like CHIP). It’s definitely an evolving field. How often are your Signatera draws?

      • Chris DavisEnglish
        1·
        8 months ago

        Every 3 months currently. The wait for results is always nail-biting. Trying to trust the process and my oncology team’s interpretation.